Preventing periprosthetic joint infection after total joint arthroplasty in high-risk patients
Conditions
Interventions
Control group (standard prevention):?Preoperatively: prophylactic intravenous 1.5g of cefuroxime sodium was given within 1 hour prior to surgical skin incision. ?Postoperative: Prophylactic intravenou
Test group (extended oral prophylaxis):?Preoperatively: prophylactic intravenous 1.5g of cefuroxime sodium was given within 1 hour prior to surgical skin incision. ?Postoperative: Prophylactic intrave
Sponsors
First Affiliated Hospital of Xinjiang Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1)The investigator judged that the subjects met the surgical indications for primary total joint arthroplasty (hip/knee) surgery. (2)Subjects underwent unilateral primary total joint arthroplasty (hip/knee) at our center. (3)Age between 18 and 80 years old (inclusive). (4)Subjects agreed and signed an informed consent form approved by the ethics committee prior to any study procedures. (5)Subjects are willing and able to participate in the prescribed follow-up visits, and can complete the research activities.
Exclusion criteria
Exclusion criteria: (1)Combination of other local or systemic infections, such as septic arthritis, joint tuberculosis, etc., or routine blood tests suggesting a white blood cell count = 10*109/L. (2)Preoperative serum C-reactive protein and erythrocyte sedimentation rate were abnormal (CRP>10mg/L or ESR>30mm/h), and suspected joint infection was considered after arthrocentesis. (3)Combined with bone tumors or malignant tumors at other sites. (4)Subjects are unable to tolerate the procedure due to other medical conditions. (5)Subjects have a clear history of allergy to fluoroquinolones or cephalosporins. (6)Subjects are participating in other clinical trials. (7)Subjects were unwilling or unable to sign the informed consent form on their own. (8)The investigator believes that the subject has other diseases or conditions that are not suitable for participating in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Infection rate; | — |
Countries
China
Contacts
Public ContactLi Cao
First Affiliated Hospital of Xinjiang Medical University
Outcome results
None listed